WR, LB and Friends. <b>NO HYPESTERS OR SCAMMERS</b> Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Wayne Rumball who wrote (10687)	5/14/1999 6:59:00 AM
From: ColleenB	Read Replies (1) of 13776

FWIW, you might want to keep an eye on LAZT today. Industry Lasertec is about to announce the results of human trials for what it says will be a revolutionary cancer treatment. LAZT announced the 100% successful completion of animal trials in late 1997 and has been conducting human trials of its Photo Therapy Resonance System in France which have thus far apparently been very successful. The trials have been conducted for bladder cancer and apparently will be transferable to other cancers, such as skin and vocal chord cancers. A Press Conference has been scheduled for 10am Friday in Atlanta to announce the results of the human trials as well as the timetable for FDA approval in the US. The CEO of PennyStocks4U.Com has been invited to the Press Conference and should report the results as well as our opinion of the future of LAZT as soon as possible thereafter. This is one of the rare times when a mid-day update from Pennystocks4u.com might be deemed necessary. Financials We consider LAZT highly speculative due to the lack of details thus far on their 'revolutionary technology', no medical journal articles, and poor descriptions of the technical details. If all goes well at the Press Conference then LAZT will move considerably higher with incredible potential. On March 28, 1999 LAZT announced that they have secured $40M in financing, which should be plenty for the foreseeable future. LAZT is in talks for Private Placements totaling about $7.5M which the company says will be more than enough to carry it through the proposed FDA trials. Lasertec has also received a buyout offer for 51% of the company at $4 per share. This buyout offer has not been approved and was not solicited by the company; Lasertec only says that talks are in progress. Lasertec has approximately 18M total outstanding shares. We were unable to confirm the float size with the company but it appears to be around 4M. Lasertec has announced that they plan to move to the Nasdaq-Small Cap but have not released a timetable. Audited financials should be complete and will be released upon finalization of the Private Placements. Lasertec also has products which they claim are able to detect bacteria and other impurities in various liquids via a patented laser technique. We have no financial information regarding the profitability of this product but expect that the cancer treatments will overshadow everything else if successful. We expect releases of detailed scientific analysis of the human trials either during the Press Conference or shortly thereafter. Conclusion We consider LAZT a highly-speculative prospect with extreme upside potential. The Press Conference on Friday will explain the scientific basis for the research and the prospects for the future. We believe that LAZT is a worthwhile risk given the incredible upside potential but we strongly advise that our subscribers read through the research we have posted here and stay tuned to our website Friday for updates shortly after the Press Conference. pennystocks4u.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next